fda d.i.s.c.o.: fda approval of cabozantinib for hepatocellular carcinoma
Published 3 months ago • 21 plays • Length 5:31Download video MP4
Download video MP3
Similar videos
-
0:54
dr. singal on the fda approval of cabozantinib in hcc
-
3:21
fda d.i.s.c.o.: intro by dr. richard pazdur
-
1:18
dr. abou-alfa on the fda approval of cabozantinib in hcc
-
6:01
fda d.i.s.c.o.: first tissue/site agnostic cancer treatment approval
-
2:12
low platelets and low red blood cell count as a side effect of multiple myeloma treatment
-
4:00
cancer immunotherapy - pd-1 and pd-l1
-
31:54
pancreatic cancer breakout: new potential in pancreatic cancer
-
8:16
fda approvals in hcc and gastric cancer, odac panel splits on adjuvant rcc treatment, and more
-
8:07
fda approval in lung cancer, priority reviews in hcc and nhl, and an odac recommendation
-
1:49
fda approval of durvalumab for bladder cancer
-
3:19
fda approval of durvalumab for advanced bladder cancer
-
10:47
fda approvals in myeloma and itp, applications accepted in myeloma and more
-
10:41
fda approvals in ovarian cancer and for mec chemo, promising data in lung cancer, and more
-
7:05
the fda approval of atezolizumab in bladder cancer
-
0:46
fda approves capmatinib for advanced lung cancer
-
10:39
fda approvals in ovarian cancer, merkel cell carcinoma, itp, and more
-
9:02
fda approval in sarcoma, priority reviews in mcrpc and myeloma, and more
-
0:37
dr. petrylak on fda approval of nivolumab in bladder cancer
-
0:38
dr. petrylak on fda approval of pembrolizumab in bladder cancer
-
0:38
dr. siefker-radtke on fda approval of avelumab in bladder cancer
-
0:53
dr. siefker-radtke on fda approval of durvalumab in bladder cancer